MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma
Authors:
- 1 October 2018
- journal article
- letter
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 13 (10) , e202-e204
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma PatientsClinical Cancer Research, 2018
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2005